Inovio Pharma (NASDAQ: INO) reported Q2 EPS of $, $0.19 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $20.4 million versus the consensus estimate of $16.29 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.